Working… Menu
Trial record 36 of 154 for:    Dermatitis, Atopic, 8

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03747575
Recruitment Status : Recruiting
First Posted : November 20, 2018
Last Update Posted : October 3, 2019
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This study will assess the efficacy and safety of MSTT1041A in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: MSTT1041A Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis
Actual Study Start Date : February 6, 2019
Estimated Primary Completion Date : April 24, 2020
Estimated Study Completion Date : April 24, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: Treatment
Participants will receive MSTT1041A
Drug: MSTT1041A
Participants will receive subcutaneous (SC) MSTT1041A

Placebo Comparator: Placebo
Participants will receive placebo matched to MSTT1041A
Drug: Placebo
Participants will receive SC placebo

Primary Outcome Measures :
  1. Percent Change of Total Eczema Area and Severity Index (EASI) Score [ Time Frame: Baseline, Week 16 ]

Secondary Outcome Measures :
  1. Proportion of Participants who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1 [ Time Frame: Baseline, Week 16 ]
  2. Proportion of Participants who Achieve >/=75% Reduction from Baseline in Eczema Area and Severity Index (EASI-75) Score [ Time Frame: Baseline, Week 16 ]
  3. Percent Change in Pruritus as Assessed by a Numeric Rating Scale (NRS) [ Time Frame: Baseline, Week 16 ]
  4. Percent Change in Body Surface Area (BSA) with Atopic Dermatitis (AD) Involvement [ Time Frame: Baseline, Week 16 ]
  5. Percent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD) [ Time Frame: Baseline, Week 16 ]
  6. Percentage of Participants with Adverse Events (AE) [ Time Frame: Up to Week 24 ]
  7. Serum Concentrations of MSTT1041A [ Time Frame: At pre-defined intervals from baseline up to Week 24 ]
  8. Incidence of Treatment-Emergent Anti-Drug Antibodies (ADAs) [ Time Frame: Up to Week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Ability to comply with the study protocol
  • Chronic AD that has been present for at least 3 years before the screening visit
  • Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications (medications or treatments applied directly to part of the body) or for whom topical treatments are otherwise medically inadvisable

Exclusion criteria

  • Prior treatment with MSTT1041A
  • Treatment with any investigational therapy (with the exception of biologics) within 8 weeks or within 5 half-lives whichever is longer, before screening
  • Treatment with any cell-depleting agents within 6 months before screening, or until lymphocyte count returns to normal, whichever is longer
  • Treatment with other biologics within 3 months or 5 half-lives before screening, whichever is longer
  • Comorbid conditions that may interfere with evaluation of investigational medicinal product
  • History or evidence of substance abuse that would pose a risk to participant safety, interfere with the conduct of the study, have an impact on the study results, or affect the participant's ability to participate in the study
  • History of anaphylaxis, hypersensitivity to a biologic agent, or known hypersensitivity to any component of the MSTT1041A or placebo injection
  • Planned surgical intervention during the course of the study
  • Pregnant or breastfeeding, or intending to become pregnant during the study
  • Participant who is a member of the investigational team or his/her immediate family

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03747575

Layout table for location contacts
Contact: Reference Study ID Number: GS40965 888-662-6728 (U.S. and Canada)

  Show 34 Study Locations
Sponsors and Collaborators
Genentech, Inc.
Layout table for investigator information
Study Director: Clinical Trials Genentech, Inc.

Layout table for additonal information
Responsible Party: Genentech, Inc. Identifier: NCT03747575     History of Changes
Other Study ID Numbers: GS40965
2018-003429-27 ( EudraCT Number )
First Posted: November 20, 2018    Key Record Dates
Last Update Posted: October 3, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases